Should I buy or sell Fulgent Genetics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FLGT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares. View FLGT analyst ratings or view top-rated stocks .

What is Fulgent Genetics' stock price target for 2024?

2 Wall Street research analysts have issued twelve-month target prices for Fulgent Genetics' stock. Their FLGT share price targets range from $25.00 to $35.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 49.2% from the stock's current price. View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts .

How have FLGT shares performed in 2024?

Fulgent Genetics' stock was trading at $28.91 on January 1st, 2024. Since then, FLGT shares have decreased by 30.4% and is now trading at $20.11. View the best growth stocks for 2024 here .

When is Fulgent Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our FLGT earnings forecast .

How can I listen to Fulgent Genetics' earnings call?

Fulgent Genetics will be holding an earnings conference call on Friday, May 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.61. The firm earned $70.51 million during the quarter, compared to the consensus estimate of $67.14 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 3.04% and a negative net margin of 58.03%.

What ETFs hold Fulgent Genetics' stock?

ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM) , ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Genomics & Biotechnology ETF (GNOM) . First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) .

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of -1.050--1.050 for the period, compared to the consensus earnings per share estimate of -0.950. The company issued revenue guidance of $280.0 million-$280.0 million, compared to the consensus revenue estimate of $294.2 million.

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA) , CRISPR Therapeutics (CRSP) , Inseego (INSG) , NeoGenomics (NEO) , Invitae (NVTA) , Block (SQ) , JD.com (JD) , Marvell Technology (MRVL) , Teladoc Health (TDOC) and Editas Medicine (EDIT) .

When did Fulgent Genetics IPO?

Fulgent Genetics (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

How do I buy shares of Fulgent Genetics?

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Fulgent Genetics have any subsidiaries?

The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics. Read More

NASDAQ:FLGT

Fulgent Genetics (FLGT) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free FLGT Stock Alerts

$20.11

+0.02 (+0.10%)

(As of 04/18/2024 ET)

Compare

Today's Range: $19.90
▼
$20.46
50-Day Range: $20.09
▼
$26.17
52-Week Range: $19.88
▼
$44.09

Volume: 219,570 shs
Average Volume: 202,980 shs
Market Capitalization: $601.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.00

Get Fulgent Genetics alerts:

Fulgent Genetics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 49.2% Upside
$30.00 Price Target
Short Interest: Healthy
3.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: -0.34
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.04) to ($1.66) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.99 out of 5 stars

Medical Sector

174th out of 918 stocks

Medical Laboratories Industry

7th out of 19 stocks

3.0

Analyst's Opinion

Consensus Rating
Fulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Fulgent Genetics has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.02% of the float of Fulgent Genetics has been sold short.
Short Interest Ratio / Days to Cover
Fulgent Genetics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Fulgent Genetics has recently decreased by 1.18%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Fulgent Genetics does not currently pay a dividend.
Dividend Growth
Fulgent Genetics does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Fulgent Genetics has received a 58.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Private genetic testing services", "Private infectious disease diagnostics services", and "Private medical laboratory services" products. See details.
Environmental Sustainability
The Environmental Impact score for Fulgent Genetics is -0.67.

0.9

News and Social Media Coverage

News Sentiment
Fulgent Genetics has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Fulgent Genetics this week, compared to 1 article on an average week.
Search Interest
Only 9 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fulgent Genetics insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Fulgent Genetics are expected to grow in the coming year, from ($2.04) to ($1.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fulgent Genetics is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fulgent Genetics is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fulgent Genetics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Fulgent Genetics Stock (NASDAQ:FLGT)

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

FLGT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FLGT Stock News Headlines

April 17, 2024 | morningstar.com

Fulgent Genetics Inc FLGT

April 11, 2024 | businesswire.com

Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 11, 2024 | finance.yahoo.com

Fulgent Genetics (NASDAQ:FLGT) shareholders have earned a 26% CAGR over the last five years

March 16, 2024 | finance.yahoo.com

FLGT Apr 2024 20.000 call

March 1, 2024 | seekingalpha.com

Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript

March 1, 2024 | finance.yahoo.com

Fulgent Genetics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

March 1, 2024 | finance.yahoo.com

An Intrinsic Calculation For Fulgent Genetics, Inc. (NASDAQ:FLGT) Suggests It's 32% Undervalued

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 29, 2024 | insidermonkey.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2023 Earnings Call Transcript

February 29, 2024 | finance.yahoo.com

Q4 2023 Fulgent Genetics Inc Earnings Call

February 28, 2024 | markets.businessinsider.com

Here's what to expect from Fulgent Genetics's earnings report

February 28, 2024 | finance.yahoo.com

Fulgent Genetics Inc (FLGT) Faces GAAP Loss Despite Core Revenue Growth in 2023

February 28, 2024 | businesswire.com

Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024 | seekingalpha.com

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

February 17, 2024 | finance.yahoo.com

FLGT Mar 2024 30.000 call

February 17, 2024 | finance.yahoo.com

FLGT Mar 2024 35.000 put

February 13, 2024 | finance.yahoo.com

Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024

February 12, 2024 | msn.com

CooperSurgical and Fulgent partner on newborn genetic screening panels

December 3, 2023 | finance.yahoo.com

The 3 Best Digital Health Stocks for Personalized Medicine

December 1, 2023 | seekingalpha.com

Following Up On Fulgent Genetics

November 14, 2023 | businesswire.com

Fulgent to Participate in the Piper Sandler 35 th Annual Healthcare Conference

November 14, 2023 | finance.yahoo.com

Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference

November 5, 2023 | finance.yahoo.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2023 Earnings Call Transcript

November 3, 2023 | finance.yahoo.com

Q3 2023 Fulgent Genetics Inc Earnings Call

November 3, 2023 | finance.yahoo.com

Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting

November 3, 2023 | finance.yahoo.com

Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates

See More Headlines

Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Confirmed): 5/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:FLGT
CUSIP: N/A
CIK: 1674930
Web: www.fulgentgenetics.com
Phone: (626) 350-0537
Fax: 626-454-1667
Employees: 1,184
Year Founded: 2011

Price Target and Rating

Average Stock Price Target: $30.00
High Stock Price Target: $35.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +49.2%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-167,820,000.00
Net Margins: -58.03%
Pretax Margin: -60.19%
Return on Equity: -3.04%
Return on Assets: -2.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.96
Quick Ratio: 6.96

Sales & Book Value

Annual Sales: $289.21 million
Price / Sales: 2.08
Cash Flow: $3.15 per share
Price / Cash Flow: 6.38
Book Value: $38.24 per share
Price / Book: 0.53

Miscellaneous

Outstanding Shares: 29,900,000
Free Float: 20,404,000
Market Cap: $601.29 million
Optionable: Optionable
Beta: 1.43

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Ming Hsieh (Age 68)
Chairman & CEO
Comp: $1.66M
Mr. Jian Xie (Age 58)
COO & President
Comp: $755.73k
Mr. Paul Kim (Age 57)
Chief Financial Officer
Comp: $757.59k
Dr. Hanlin Gao D.A.B.M.G. (Age 57)
FACMG, M.D., Ph.D., Chief Scientific Officer & Laboratory Director
Comp: $630.61k
Ms. Natalie Prescott
General Counsel & Chief Privacy Officer
Ms. Doreen Ng
VP of Operations & Compliance and GM of Houston Office
Mr. Jakub Sram
Vice President of Business Development & Sales
Ms. Ellen Tsui
Vice President of Human Resources
Mr. Brandon Perthuis
Chief Commercial Officer
Dr. Lawrence M. Weiss M.D. (Age 67)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FLGT Stock Analysis - Frequently Asked Questions

Should I buy or sell Fulgent Genetics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FLGT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.
View FLGT analyst ratings or view top-rated stocks.
What is Fulgent Genetics' stock price target for 2024?: 2 Wall Street research analysts have issued twelve-month target prices for Fulgent Genetics' stock. Their FLGT share price targets range from $25.00 to $35.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 49.2% from the stock's current price.
View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts.
How have FLGT shares performed in 2024?: Fulgent Genetics' stock was trading at $28.91 on January 1st, 2024. Since then, FLGT shares have decreased by 30.4% and is now trading at $20.11.
View the best growth stocks for 2024 here.
When is Fulgent Genetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our FLGT earnings forecast.
How can I listen to Fulgent Genetics' earnings call?: Fulgent Genetics will be holding an earnings conference call on Friday, May 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Fulgent Genetics' earnings last quarter?: Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.61. The firm earned $70.51 million during the quarter, compared to the consensus estimate of $67.14 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 3.04% and a negative net margin of 58.03%.

What ETFs hold Fulgent Genetics' stock?: ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Genomics & Biotechnology ETF (GNOM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).
What guidance has Fulgent Genetics issued on next quarter's earnings?: Fulgent Genetics updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of -1.050--1.050 for the period, compared to the consensus earnings per share estimate of -0.950. The company issued revenue guidance of $280.0 million-$280.0 million, compared to the consensus revenue estimate of $294.2 million.
What other stocks do shareholders of Fulgent Genetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).
When did Fulgent Genetics IPO?: Fulgent Genetics (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.
How do I buy shares of Fulgent Genetics?: Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Fulgent Genetics have any subsidiaries?: The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.
Read More

This page (NASDAQ:FLGT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fulgent Genetics (FLGT) Stock Price, News & Analysis

Fulgent Genetics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Fulgent Genetics Stock (NASDAQ:FLGT)

FLGT Stock Price History

FLGT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

FLGT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™